Health Care: Adrenal Cortical Extract Taken Off Drug Market: HRD-81-61

 
9781289000677: Health Care: Adrenal Cortical Extract Taken Off Drug Market: HRD-81-61
View all copies of this ISBN edition:
 
 

Adrenal cortical extract (ACE) products were once recommended in the treatment of Addison's disease and for several other indications including hypoglycemia. In January 1978, the Food and Drug Administration (FDA) advised drug firms marketing ACE products that the drug represented a substantial risk of undertreatment because of its low potency and the resulting potential hazard to patients.
A review of current well-known textbooks on medicine and endocrinology showed a unanimous preference for using synthetic compounds in the treatment of both the chronic and acute phases of Addison's disease. GAO could not find any medical support for using ACE products in the treatment of hypoglycemia. The regulatory actions taken by FDA against ACE were within its legal authority under the Food, Drug, and Cosmetic Act and were not unreasonable. The use of alternative procedures would have afforded all interested parties a better opportunity to comment on FDA findings and proposed actions; however, the affected drug firms had an opportunity to challenge FDA findings and did not.

"synopsis" may belong to another edition of this title.

Buy New View Book
List Price: US$ 15.75
US$ 16.48

Convert currency

Shipping: FREE
From United Kingdom to U.S.A.

Destination, rates & speeds

Add to Basket

Top Search Results from the AbeBooks Marketplace

1.

Published by Bibliogov, United States (2013)
ISBN 10: 1289000670 ISBN 13: 9781289000677
New Paperback Quantity Available: 10
Print on Demand
Seller:
The Book Depository
(London, United Kingdom)
Rating
[?]

Book Description Bibliogov, United States, 2013. Paperback. Condition: New. Language: English . Brand New Book ***** Print on Demand *****.Adrenal cortical extract (ACE) products were once recommended in the treatment of Addison s disease and for several other indications including hypoglycemia. In January 1978, the Food and Drug Administration (FDA) advised drug firms marketing ACE products that the drug represented a substantial risk of undertreatment because of its low potency and the resulting potential hazard to patients. A review of current well-known textbooks on medicine and endocrinology showed a unanimous preference for using synthetic compounds in the treatment of both the chronic and acute phases of Addison s disease. GAO could not find any medical support for using ACE products in the treatment of hypoglycemia. The regulatory actions taken by FDA against ACE were within its legal authority under the Food, Drug, and Cosmetic Act and were not unreasonable. The use of alternative procedures would have afforded all interested parties a better opportunity to comment on FDA findings and proposed actions; however, the affected drug firms had an opportunity to challenge FDA findings and did not. Seller Inventory # AAV9781289000677

More information about this seller | Contact this seller

Buy New
US$ 16.48
Convert currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, rates & speeds

2.

Published by Bibliogov, United States (2013)
ISBN 10: 1289000670 ISBN 13: 9781289000677
New Paperback Quantity Available: 10
Print on Demand
Seller:
Book Depository International
(London, United Kingdom)
Rating
[?]

Book Description Bibliogov, United States, 2013. Paperback. Condition: New. Language: English . Brand New Book ***** Print on Demand *****. Adrenal cortical extract (ACE) products were once recommended in the treatment of Addison s disease and for several other indications including hypoglycemia. In January 1978, the Food and Drug Administration (FDA) advised drug firms marketing ACE products that the drug represented a substantial risk of undertreatment because of its low potency and the resulting potential hazard to patients. A review of current well-known textbooks on medicine and endocrinology showed a unanimous preference for using synthetic compounds in the treatment of both the chronic and acute phases of Addison s disease. GAO could not find any medical support for using ACE products in the treatment of hypoglycemia. The regulatory actions taken by FDA against ACE were within its legal authority under the Food, Drug, and Cosmetic Act and were not unreasonable. The use of alternative procedures would have afforded all interested parties a better opportunity to comment on FDA findings and proposed actions; however, the affected drug firms had an opportunity to challenge FDA findings and did not. Seller Inventory # AAV9781289000677

More information about this seller | Contact this seller

Buy New
US$ 21.00
Convert currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, rates & speeds

3.

Published by BiblioGov
ISBN 10: 1289000670 ISBN 13: 9781289000677
New Paperback Quantity Available: > 20
Print on Demand
Seller:
BuySomeBooks
(Las Vegas, NV, U.S.A.)
Rating
[?]

Book Description BiblioGov. Paperback. Condition: New. This item is printed on demand. 44 pages. Dimensions: 9.7in. x 7.4in. x 0.1in.Adrenal cortical extract (ACE) products were once recommended in the treatment of Addisons disease and for several other indications including hypoglycemia. In January 1978, the Food and Drug Administration (FDA) advised drug firms marketing ACE products that the drug represented a substantial risk of undertreatment because of its low potency and the resulting potential hazard to patients. A review of current well-known textbooks on medicine and endocrinology showed a unanimous preference for using synthetic compounds in the treatment of both the chronic and acute phases of Addisons disease. GAO could not find any medical support for using ACE products in the treatment of hypoglycemia. The regulatory actions taken by FDA against ACE were within its legal authority under the Food, Drug, and Cosmetic Act and were not unreasonable. The use of alternative procedures would have afforded all interested parties a better opportunity to comment on FDA findings and proposed actions; however, the affected drug firms had an opportunity to challenge FDA findings and did not. This item ships from La Vergne,TN. Paperback. Seller Inventory # 9781289000677

More information about this seller | Contact this seller

Buy New
US$ 21.21
Convert currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, rates & speeds

4.

U.S. Government Accountability Office (G
Published by BiblioGov (2016)
ISBN 10: 1289000670 ISBN 13: 9781289000677
New Paperback Quantity Available: 1
Print on Demand
Seller:
Ria Christie Collections
(Uxbridge, United Kingdom)
Rating
[?]

Book Description BiblioGov, 2016. Paperback. Condition: New. PRINT ON DEMAND Book; New; Publication Year 2016; Not Signed; Fast Shipping from the UK. No. book. Seller Inventory # ria9781289000677_lsuk

More information about this seller | Contact this seller

Buy New
US$ 16.37
Convert currency

Add to Basket

Shipping: US$ 4.89
From United Kingdom to U.S.A.
Destination, rates & speeds

5.

Published by BiblioGov (2013)
ISBN 10: 1289000670 ISBN 13: 9781289000677
New Softcover Quantity Available: 1
Seller:
Irish Booksellers
(Portland, ME, U.S.A.)
Rating
[?]

Book Description BiblioGov, 2013. Condition: New. book. Seller Inventory # M1289000670

More information about this seller | Contact this seller

Buy New
US$ 32.36
Convert currency

Add to Basket

Shipping: US$ 3.27
Within U.S.A.
Destination, rates & speeds

6.

BiblioGov
Published by BiblioGov (2013)
ISBN 10: 1289000670 ISBN 13: 9781289000677
New Paperback Quantity Available: 1
Seller:
Books Express
(Portsmouth, NH, U.S.A.)
Rating
[?]

Book Description BiblioGov, 2013. Paperback. Condition: New. Ships with Tracking Number! INTERNATIONAL WORLDWIDE Shipping available. Buy with confidence, excellent customer service!. Seller Inventory # 1289000670n

More information about this seller | Contact this seller

Buy New
US$ 102.87
Convert currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, rates & speeds